Skip to main content

Table 1 Immune checkpoint inhibitors in first-line treatment in advanced non-small cell lung cancer patients

From: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

Study Phase n RR (%) PFS (months) OS (months) AEs ≥ grade 3 (%)
KEYNOTE 024 [15] Pembrolizumab vs. CT III 305
PD-L1 ≥ 50%a
44.8 vs. 27.8
P < 0.001
10.3 vs. 6.0
HR, 0.50; P < 0.001
HR, 0.60; P = 0.005
1-year OS: 70% vs. 54%
26.6 vs. 53.3
CheckMate 026 [31] Nivolumab vs. CT III 423
PD-L1 ≥ 5%b
26.1 vs. 33.5 4.2 vs. 5.9
HR, 1.15; P = 0.251
HR, 1.02
14.4 vs. 13.2 months
17.6 vs. 50.6
KEYNOTE 021 [39] Pembrolizumab + CT vs. CT II 123 55 vs. 29
P = 0.0016
13.0 vs. 8.9
HR, 0.53; P = 0.0102
HR, 0.90; P = 0.39 39 vs. 26
CheckMate 012 [42]
Nivolumab + Ipilimumab/12 weeks until disease progression or toxicity
Nivolumab + Ipilimumab/6 weeks until disease progression or toxicity
I 38
40
47
38
8.1
3.9
Not calculated 37
33
  1. CT chemotherapy, RR response rate, PFS progression-free survival, OS overall survival, AEs adverse events
  2. aExpression in ≥ 50% of tumor cells, regardless of the staining intensity with the 22C3 clone
  3. bTumor cell membrane staining any intensity > 1% with the 28-8 clone Epitomics